Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Melanoma 4Colitis 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Hepatitis 1

Interventions

atezolizumab 2vedolizumab 1Taste 1Radiotherapy 1National Cancer Institute (U.S.) 1Loperamide 1LDP-02 1Interleukin-2 1Infliximab 1Immunotherapy 1Immunoglobulin G 1Fecal Microbiota Transplantation 1Fatty Acids, Omega-3 1Drug Therapy 1Disulfides 1CT-P13 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × vedolizumab × Dermatologic × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡